Thyrotropin-releasing hormone analogs and method of use
AssigneeGeorgetown University
InventorAlan I. Faden
Life of this patent
Estimating the term…
Abstract
A series of novel thyrotropin-releasing hormone analogs wherein the C-terminal prolineamide moiety has been preserved, the N-terminal moiety comprises one of five different ring structures and the histidyl moiety is substituted with CF.sub.3, NO.sub.2 or a halogen. A method of use of the analog for the treatment of neurologic disorders is also provided.
Claims24
A compound having the following formula:
- ##STR9## wherein R" is selected from the group consisting of:
- ##STR10## R and R' are both I.
A compound having the following formula:
- ##STR12## wherein R and R' are respectively:
- (a) halogen and halogen;
- (b) halogen and hydrogen;
- (c) CF.sub.3 and hydrogen;
- (d) hydrogen and CF.sub.3 ;
- or
- (e) NO.sub.2 and hydrogen.
A method for the treatment of effects of neurologic damage in an animal, comprising administering to an animal suffering from neurologic damage a neurologic damage effect treating effective amount of a compound having the following formula:
- ##STR16## wherein R" is selected from the group consisting of:
- ##STR17## wherein R and R' are respectively:
- (a) halogen and halogen;
- (b) halogen and hydrogen;
- (c) CF.sub.3 and hydrogen;
- (d) hydrogen and CF.sub.3 ;
- or
- (e) NO.sub.2 and hydrogen,
- wherein said neurologic damage is brain trauma.
A method for the treatment of effects of neurologic damage in an animal, comprising administering to an animal suffering from neurologic damage a neurologic damage effect treating effective amount of a compound having the following formula:
- ##STR18## wherein R" is selected from the group consisting of:
- ##STR19## wherein R and R' are respectively:
- (a) halogen and halogen;
- (b) halogen and hydrogen;
- (c) CF.sub.3 and hydrogen;
- (d) hydrogen and CF.sub.3 ;
- or
- (e) NO.sub.2 and hydrogen,
- wherein said neurologic damage is caused by a stroke.
A method for the treatment of effects of neurologic damage in an animal, comprising administering to an animal suffering from neurologic damage a neurologic damage effect treating effective amount of a compound having the following formula:
- ##STR20## wherein R" is selected from the group consisting of:
- ##STR21## wherein R and R' are respectively:
- (a) halogen and halogen;
- (b) halogen and hydrogen;
- (c) CF.sub.3 and hydrogen;
- (d) hydrogen and CF.sub.3 ;
- or
- (e) NO.sub.2 and hydrogen,
- wherein said neurologic damage is caused by anesthesia or a drug overdose.
A method for the treatment of effects of neurologic damage in an animal, comprising administering to an animal suffering from neurologic damage a neurologic damage effect treating effective amount of a compound having the following formula:
- ##STR22## wherein R" is selected from the group consisting of:
- ##STR23## wherein R and R' are are both I and wherein said neurologic damage is selected from the group consisting of brain trauma and spinal cord trauma.
A method for the treatment of effects of neurologic damage in an animal, comprising administering to an animal suffering from neurologic damage a neurologic damage effect treating effective amount of a compound having the following formula:
- ##STR25## wherein R and R' are respectively:
- (a) halogen and halogen;
- (b) halogen and hydrogen;
- (c) CF.sub.3 and hydrogen;
- (d) hydrogen and CF.sub.3 ;
- or
- (e) NO.sub.2 and hydrogen;
- and wherein said neurologic damage is selected from the group consisting of brain trauma and spinal cord trauma.
Dependencies are inferred from the claim text.